Evidence map›Paper›PMID 33442986›Full record

ArticleNanomedicine (London, England)2021

Alfalfa mosaic virus nanoparticles-based

Mehdi Shahgolzari, Maghsoud Pazhouhandeh, Morteza Milani, Steven Fiering, Ahmad Yari Khosroushahi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  4. Review
  5. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.ACS biomaterials science & engineering · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehdi ShahgolzariDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Maghsoud PazhouhandehBiotechnology Dept. Agriculture Fac. Azarbaijan Shahid Madani University, Tabriz, Iran.
Morteza MilaniDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Steven FieringDepartment of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03756, USA.
Ahmad Yari KhosroushahiDepartment of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0003-3854-7311

Funding

Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.U01CA218292 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, STEINMETZ, NICOLE FRANZISKA · 2017 to 2021
$3.0M
NCI NIH HHS U01 CA218292
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alfalfa mosaic virusNanoparticlesNeoplasmsAnimalsImmunityImmunotherapyMiceVaccinationAMVISVPVNPTME

Identifiers

PMID33442986
PMCPMC8173499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.